289 related articles for article (PubMed ID: 32284554)
1. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours.
Mansurov A; Ishihara J; Hosseinchi P; Potin L; Marchell TM; Ishihara A; Williford JM; Alpar AT; Raczy MM; Gray LT; Swartz MA; Hubbell JA
Nat Biomed Eng; 2020 May; 4(5):531-543. PubMed ID: 32284554
[TBL] [Abstract][Full Text] [Related]
2. Targeted antibody and cytokine cancer immunotherapies through collagen affinity.
Ishihara J; Ishihara A; Sasaki K; Lee SS; Williford JM; Yasui M; Abe H; Potin L; Hosseinchi P; Fukunaga K; Raczy MM; Gray LT; Mansurov A; Katsumata K; Fukayama M; Kron SJ; Swartz MA; Hubbell JA
Sci Transl Med; 2019 Apr; 11(487):. PubMed ID: 30971453
[TBL] [Abstract][Full Text] [Related]
3. Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker.
Mansurov A; Hosseinchi P; Chang K; Lauterbach AL; Gray LT; Alpar AT; Budina E; Slezak AJ; Kang S; Cao S; Solanki A; Gomes S; Williford JM; Swartz MA; Mendoza JL; Ishihara J; Hubbell JA
Nat Biomed Eng; 2022 Jul; 6(7):819-829. PubMed ID: 35534574
[TBL] [Abstract][Full Text] [Related]
4. An IL-12-Based Nanocytokine Safely Potentiates Anticancer Immunity through Spatiotemporal Control of Inflammation to Eradicate Advanced Cold Tumors.
Chen P; Yang W; Nagaoka K; Huang GL; Miyazaki T; Hong T; Li S; Igarashi K; Takeda K; Kakimi K; Kataoka K; Cabral H
Adv Sci (Weinh); 2023 Apr; 10(10):e2205139. PubMed ID: 36739605
[TBL] [Abstract][Full Text] [Related]
5. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.
Voeller J; Erbe AK; Slowinski J; Rasmussen K; Carlson PM; Hoefges A; VandenHeuvel S; Stuckwisch A; Wang X; Gillies SD; Patel RB; Farrel A; Rokita JL; Maris J; Hank JA; Morris ZS; Rakhmilevich AL; Sondel PM
J Immunother Cancer; 2019 Dec; 7(1):344. PubMed ID: 31810498
[TBL] [Abstract][Full Text] [Related]
6. Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape.
Hicks KC; Chariou PL; Ozawa Y; Minnar CM; Knudson KM; Meyer TJ; Bian J; Cam M; Schlom J; Gameiro SR
Nat Commun; 2021 Aug; 12(1):5151. PubMed ID: 34446712
[TBL] [Abstract][Full Text] [Related]
7. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
[TBL] [Abstract][Full Text] [Related]
8. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.
Landsberg J; Kohlmeyer J; Renn M; Bald T; Rogava M; Cron M; Fatho M; Lennerz V; Wölfel T; Hölzel M; Tüting T
Nature; 2012 Oct; 490(7420):412-6. PubMed ID: 23051752
[TBL] [Abstract][Full Text] [Related]
9. Recruitment of CD103
Williford JM; Ishihara J; Ishihara A; Mansurov A; Hosseinchi P; Marchell TM; Potin L; Swartz MA; Hubbell JA
Sci Adv; 2019 Dec; 5(12):eaay1357. PubMed ID: 31844672
[TBL] [Abstract][Full Text] [Related]
10. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells.
Zou JP; Yamamoto N; Fujii T; Takenaka H; Kobayashi M; Herrmann SH; Wolf SF; Fujiwara H; Hamaoka T
Int Immunol; 1995 Jul; 7(7):1135-45. PubMed ID: 8527411
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.
Newton MR; Askeland EJ; Andresen ED; Chehval VA; Wang X; Askeland RW; O'Donnell MA; Luo Y
Clin Exp Immunol; 2014 Jul; 177(1):261-8. PubMed ID: 24593764
[TBL] [Abstract][Full Text] [Related]
12. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
13. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
14. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.
Lu S; Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Li Z; Wu JD
Clin Cancer Res; 2015 Nov; 21(21):4819-30. PubMed ID: 26106076
[TBL] [Abstract][Full Text] [Related]
15. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
[TBL] [Abstract][Full Text] [Related]
16. Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice.
Lasek W; Basak G; Switaj T; Jakubowska AB; Wysocki PJ; Mackiewicz A; Drela N; Jalili A; Kamiński R; Kozar K; Jakóbisiak M
Cancer Immunol Immunother; 2004 Apr; 53(4):363-72. PubMed ID: 14605763
[TBL] [Abstract][Full Text] [Related]
17. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-12 activated CD8
Yang SX; Wei WS; Ouyan QW; Jiang QH; Zou YF; Qu W; Tu JH; Zhou ZB; Ding HL; Xie CW; Lei QM; Zhong CR
Biomed Pharmacother; 2016 Dec; 84():1466-1471. PubMed ID: 27810342
[TBL] [Abstract][Full Text] [Related]
19. Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer.
Cicchelero L; Denies S; Haers H; Vanderperren K; Stock E; Van Brantegem L; de Rooster H; Sanders NN
Vet Comp Oncol; 2017 Dec; 15(4):1187-1205. PubMed ID: 27506827
[TBL] [Abstract][Full Text] [Related]
20. Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs.
Song S; Wang Y; Wang J; Lian W; Liu S; Zhang Z; Liu F; Wei L
Eur J Cancer; 2012 Sep; 48(14):2252-9. PubMed ID: 22230748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
